Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
myDC and pDC Vaccination in Stage III Melanoma
NCT02574377Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2015
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: Immunogenicity - Type I IFN Gene Expression up to 1.5 years, Immunogenicity - Response to KLH up to 1.5 years and 1 more. Started Sep 2015; status: completed.
02
Conditions
melanoma
Beyond the preview
Go deeper on NCT02574377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574377.